Early Detection of Residual Breast Cancer through a Robust, Scalable and Personalized Analysis of Circulating Tumour DNA (ctDNA) Antedates O

The potential utility of circulating tumor DNA (ctDNA) to detect minimal residual disease (MRD) following surgery and/or adjuvant therapy and to monitor metastatic disease has been demonstrated.